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Background: Long Non-coding RNAs (lncRNA) are emerging as essential regulators
of genetic and epigenetic networks, and their deregulation may underlie complex
diseases, such as carcinogenesis. Several studies have described lncRNAs alterations in
patients with solid tumors. In particular, in Gastrointestinal Stromal Tumors (GIST),
upregulation of HOTAIR has been associated with aggressiveness, metastasis, and poor
patients’ survival. In order to gain more detailed insight on the molecular role of
lncRNAs in GIST, we analyzed in vivo the expression levels of lncRNAs H19 and
MALAT1 in surgically resected patients.
Material and methods: The expression of the lnc-RNAs H19 and MALAT1 was
evaluated in primary tumor tissue from 20 GIST patients undergoing surgical
resection, and paired normal mucosa samples, using quantitative real-time reverse
transcriptase qRT-PCR. The result was considered reliable if the tumor tissue
harboured at least 70% of cancer cells.
Results:H19 was evaluable in 20 patients, MALAT 1 in 8 patients. H19 was
overexpressed in 66% (12/20) cancer tissue from GIST patients, and the difference of
expression between the two groups (tumor tissue vs normal tissue) was found to be
statistically significant (P= 0.0496). MALAT1 was overexpressed also in 100% (8/8)
cancer tissue from GIST patients.
Conclusions: H19 and MALAT1 appear frequently upregulated in GIST patients.
Further analyses are needed to confirm these data, and evaluate the potential role of
such lncRNAs, as prognostic/predictive biomarkers.
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